Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from ClearPoint Neuro ( (CLPT) ) is now available.
On December 29, 2025, ClearPoint Neuro entered into a consent agreement with CALW SA LLC and TPC Investments III LP, an affiliate of Oberland Capital Management, related to an existing Note Purchase Agreement originally executed in May 2025 and amended in November 2025. Under the consent, ClearPoint Neuro agreed to complete by January 15, 2026 an internal reorganization of its Swedish subsidiary IRRAS AB, including transferring all equity interests in IRRAS USA, Inc. from IRRAS AB to ClearPoint or its direct U.S. subsidiary in exchange for a subordinated intercompany note, and to take additional steps so that IRRAS AB qualifies as an “Immaterial Foreign Subsidiary” under the Note Purchase Agreement. The consent preserves the material economic terms of the company’s financing arrangements while restructuring ownership of the IRRAS assets, which may streamline the company’s capital structure and compliance with its debt covenants following the IRRAS acquisition.
The most recent analyst rating on (CLPT) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.
Spark’s Take on CLPT Stock
According to Spark, TipRanks’ AI Analyst, CLPT is a Neutral.
ClearPoint Neuro’s overall stock score reflects strong strategic positioning and growth initiatives, particularly the merger with IRRAS, which enhances market reach and operational scale. However, the company’s current unprofitability, weak technical indicators, and lack of dividend yield weigh on the score. Continued focus on improving profitability and operational efficiency will be key to enhancing the stock’s attractiveness.
To see Spark’s full report on CLPT stock, click here.
More about ClearPoint Neuro
ClearPoint Neuro, Inc. operates in the medical technology sector, focusing on neurosurgical navigation and therapy-enabling devices and systems. The company targets hospitals and neurosurgical centers, and has recently expanded its footprint through the acquisition of IRRAS Holdings, Inc., which adds additional neurology-focused assets and international subsidiaries to its portfolio.
Average Trading Volume: 815,939
Technical Sentiment Signal: Hold
Current Market Cap: $417.4M
Find detailed analytics on CLPT stock on TipRanks’ Stock Analysis page.